Login to Your Account



Other News To Note


Wednesday, June 8, 2011
Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., and Bayer HealthCare, of Leverkusen, Germany, announced that Bayer HealthCare submitted an application for marketing authorization in Europe for VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration (wet AMD). Regeneron and Bayer HealthCare are collaborating on the global development of VEGF Trap-Eye for the treatment of wet AMD, central retinal vein occlusion, diabetic macular edema and myopic choroidal neovascularization.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription